1	Detection of early-onset severe preeclampsia by cell-free DNA fragmentome
2	
3	Running Head: Plasma DNA predict preeclampsia
4	Haiqiang Zhang ^{1†} , Longwei Qiao ^{2†} , Xintao Hu ^{1,3} , Chunhua Zhang ² , Yu Lin ¹ , Jingyu
5	Zhao ⁴ , Xiaojuan Wu ² , Xiaoyan Song ² , Hui Tang ² , Ying Xue ² , Yang Sun ¹ , Rijing Ou ¹ ,
6	Xinxin Wang ¹ , Yan Zhang ¹ , Xin Jin ^{1*} , Ting Wang ^{2,6*}
7	
8	
9	
10	
11	¹ BGI Research, Shenzhen 518083, China
12	² Center for Reproduction and Genetics, School of Gusu, The Affiliated Suzhou
13	Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Nanjing
14	Medical University, Suzhou, China
15	³ State Key Laboratory of Public Big Data, College of Computer Science and
16	Technology, Guizhou University, Guiyang, 550025, China
17	⁴ Clin Lab, BGI Genomics, Nanjing 210019, China
18	[*] Correspondence: biowt@njmu.edu.cn (T.W.), jinxin@genomics.cn (X.J.)
19	[†] These authors contributed equally
20	
21	

22 Acknowledgement

We would like to thank China National GeneBank (CNGB) for the technical
support.

26

27 Abstract

28 Early-onset severe preeclampsia (EO-PE) is a distinct and highly consequential form 29 of preeclampsia (PE), presenting significant challenges for early detection. Here, we 30 investigated the fragmentation pattern of plasma cell-free DNA (cfDNA) in EO-PE 31 patients. We uncovered that the nucleotide composition at the 5' end (i.e. ends motif) 32 of plasma cfDNA showed a unique pathological preference in EO-PE pregnancies and 33 gestational-psychology preference in healthy pregnancies. By integrating 91 EO-PE 34 specific motifs into a machine-learning model, we achieved accurate prediction of 35 EO-PE development in early pregnancies. Remarkably, our model demonstrated 36 robust performance in an independent cohort of 74 early pregnancies and 1,241 37 non-invasive prenatal testing (NIPT) samples with ultra-low sequencing depth. 38 Additionally, we revealed that these PE-specific motif signatures lacked tissue 39 specificity, originating extracellularly, and were associated with the abnormal 40 concentration of DNA fragmentation factor subunit beta (DFFB) in EO-PE patients' 41 plasma. These findings establish the plasma DNA fragmentome as a non-invasive and

42	cost-effective biomarker that can be simultaneously captured during NIPT for early EO-PE
43	detection and provide valuable insights into cfDNA production mechanisms in
44	preeclampsia patients.
45	
46	Keywords: plasma DNA; end motif; non-invasive biomarker; pregnancy
47	complication
48	
49	
50	Introduction
51	Preeclampsia (PE) is one of the most serious pregnancy specific complications

52 and the leading cause of maternal and perinatal morbidity and mortality worldwide(1,

53 2). This multisystem maternal syndrome is characterized by new-onset hypertension

54 and maternal organ damage that occurs after 20 weeks of gestation(3). Among the

various forms of PE, early-onset preeclampsia, occurring before 34 weeks of gestation,

56 represents the most severe manifestation, associated with a higher incidence of

57 maternal complications, perinatal mortality, and morbidity compared to late-onset

58 PE(4, 5). However, the complex etiology, diverse clinical manifestations, and

59 pathophysiology of PE present significant challenges in terms of prediction,

60 management, and prevention(6-8). Despite extensive efforts, clinically satisfactory

61 biomarkers and prediction models for early detection of PE are lacking, primarily due

62 to limited clinical availability and low predictive efficacy(9, 10). Nevertheless, recent

63	advancements in the field of circulating cell-free DNA (cfDNA) provide new
64	opportunities for developing effective PE biomarkers. Promising results have shown
65	that cfDNA concentration is elevated in PE and correlates with disease severity(11,
66	12). Moreover, disparities in cfDNA coverage across promoter regions have been
67	observed between PE and healthy $pregnancies(13)$. However, further in-depth
68	investigations and verifications are required to assess the applicability of cfDNA in
69	early PE detection.
70	Recently, the study of cfDNA fragmentation patterns, known as
71	"fragmentomics," is an emerging field with the potential to advance our
72	understanding of cfDNA's biology and develop new biomarkers for clinical
73	applications(14). In addition to fragment size(15), recent advances in this new "omics"
74	area have identified several crucial characteristics of cfDNA fragments, including
75	nucleosome footprints(16, 17), fragment end motifs(18, 19), preferred ends(20, 21),
76	jagged ends(22), cleavage profile(23) and coverage/end imbalance in regulatory
77	elements(24, 25). These characteristics are believed to preserve valuable information
78	about the tissue of origin of cfDNA(26) For instance, the preferred ends of short and
79	long plasma cfDNA are related to fetal and maternal origin(27). The presence of
80	distinct characteristic end motifs in plasma cfDNA derived from cancers, placenta,
81	and hematopoietic cells enables the monitoring of specific pathophysiological
82	condition(28) Therefore, cfDNA fragmentomics shows great promise in clinical
83	applications, particularly for noninvasive early disease detection(29, 30).

84	In this study, we present a comprehensive analysis and comparison of end motif
85	patterns in plasma DNA from pregnancies with early-onset severe preeclampsia and
86	healthy pregnancies. Our investigation focuses on identifying specific sets of motifs
87	associated with PE pathology and gestational physiology. To validate their potential
88	for early PE detection, we assess the performance of these PE-specific motifs, and
89	notably, our findings demonstrate robust performance even with low-coverage
90	non-invasive prenatal testing (NIPT) data. Additionally, we explore the tissue origin
91	of the PE-specific motif signatures, examining their relationship with cfDNA size,
92	nucleosomal structure, and the concentrations of nucleases involved in cfDNA
93	digestion in both EO-PE and non-EO-PE pregnancies.

94

95 **Results**

96 Characteristics of pregnancies in the discovery cohort

97	For the discovery cohort (SZ-1 cohort), we collected a total of 151 plasma
98	samples from 140 pregnant women with early-onset PE (N=79) and without PE
99	(N=61) at different gestational ages. Specifically, one set of plasma samples was
100	obtained before labor during the third trimester: 16 samples were collected at the time
101	of diagnosis of early-onset severe PE (mean gestational age, 29.9 weeks) (PT3), and 8
102	samples were collected before labor from healthy control women (mean gestational
103	age, 39.7 weeks) (NT3). Another set of plasma samples was obtained during the
104	second trimester: 71 samples were collected before the diagnosis of early-onset severe
105	PE (mean gestational age, 17.6 weeks) (PT2), and 56 samples were collected from
106	gestational age-matched healthy control women (mean gestational age, 19.0 weeks)
107	(NT2). Among these subjects, 8 PE and 3 healthy pregnancies contributed plasma
108	samples at both the second and third trimesters. (Figure 1A).

109 The demographic and clinical characteristics of all subjects are shown in Table 1. 110 The maternal age, BMI, times of pregnancies and delivery were comparable between 111 PE and control subjects in both 2^{nd} and 3^{rd} trimesters. Compared with control subjects 112 (mean: 39.7 weeks), PE patients exhibited significantly lower gestational age in 113 groups of 3^{rd} trimester (mean: 29.9 weeks) (*P*-value<0.0001, Mann-Whitney U test). 114 The mean gestational age of PE onset in subjects collected at the 2^{nd} and 3^{rd} trimesters

115	were 30.0 and 29.7, respectively. The maternal plasma cfDNA of group NT2, PT2,
116	NT3, and PT3 was sequenced to a mean of 5.46 (range: 3.06 - 8.85), 5.47 (range: 2.74
117	- 16.3), 7.94 (range: 5.46 - 10.19) and 10.31 (range: 7.61 - 13.42) haploid human
118	genome coverage, respectively.

119 Ends motifs of plasma DNA specific to PE pathology and gestational physiology

120 The distribution of nucleotide string at the end of plasma DNA, referred to as 121 ends motif, was reported to embody the cfDNA fragmentation footprint(18). 122 Therefore, we wonder whether the ends motif could be used to decipher the disease 123 signatures associated with preeclampsia in circulating cell-free DNA. Accordingly, we 124 examined the diversity of 4mer ends motifs in the plasma DNA of both control and 125 PE groups using the motif diversity score (MDS)(18). The results showed that the 126 MDS values between the control (median: 0.946, range: 0.940-0.950) and 127 preeclampsia subjects (median: 0.946, range: 0.934-0.953) were comparable during 128 the second trimester (P-value=0.107; Mann-Whitney U-test). However, during the 129 third trimester, the MDS was significantly reduced in preeclampsia samples (median: 130 0.943, range: 0.932-0.949) when compared to controls (median: 0.948, range: 131 0.947-0.950) (P-value=0.003; Mann-Whitney U-test; Figure 1B), implying that 132 preeclampsia-associated ends motif signals might be enhanced as the onset of 133 preeclampsia approaches.

134 Subsequently, through the unsupervised clustering, we examined the distribution

135 patterns of all 256 types of 4-mer motifs between the healthy and PE pregnancies in 136 the third trimester. As shown in Figure 1C, EO-PE and healthy samples could be 137 readily separated into two distinct clusters, suggesting the profiles of cfDNA ends 138 motifs were highly different between pregnancies with and without EO-PE. Moreover, 139 we compared the motif frequencies between healthy and preeclampsia pregnancies at 140 different gestational ages, as well as between pregnancies during the second and third 141 trimesters in preeclampsia and healthy pregnancies. We identified four sets of motifs 142 $(Log_{10}(FC))$ ranked top and bottom 25% and Wilcox *P*-value<0.05): Set A includes 63 143 increased and 64 decreased motifs that exhibited a significant increase and decrease, 144 respectively, in PT3 relative to NT3; Set B includes 58 increased and 50 decreased 145 motifs that exhibited a significant increase and decrease, respectively, in PT2 relative 146 to NT2; Set C includes 63 increased and 62 decreased motifs that exhibited a 147 significant increase and decrease, respectively, in PT3 relative to PT2; and Set D 148 includes 56 increased and 45 decreased motifs that exhibited a significant increase 149 and decrease, respectively, in NT3 relative to NT2 (Figure 1D and Supplemental 150 Table 1). The top 10 increased and decreased motifs of each set are shown in 151 Supplementary Figure 1.

Notably, we observed that in both the second and third trimesters, the motifs that were significantly elevated in preeclampsia samples predominantly began with A and C (PT3: 95.24%, PT2: 96.55%), while significantly reduced motifs in preeclampsia samples mainly started with T and G (PT3: 93.75%, PT2: 96%). Such pattern was

156	further pronounced in PT3 pregnancies compared to PT2 pregnancies (A% and C%
157	among increased motifs: 96.83%, T% and G% among decreased motifs: 91.94%),
158	thus demonstrating that the PE-specific motif signals become stronger as the onset of
159	the condition approaches (Figure 1E, F). In contrast, this PE-specific signal was
160	absent in healthy pregnancies between different gestational ages (Figure 1E).
161	Compared with NT2, we found that in the NT3 group, the motifs starting with A and
162	C only accounted for 57.14% of the significantly increased motifs, and the motifs
163	began with G and T only accounted for 48.89% of the significantly decreased motifs
164	(Figure 1F).
165	To quantify the signatures of preeclampsia in plasma DNA, motif ratios between
166	the frequencies of increased and decreased motifs of Set A were calculated in PE and
167	control pregnancies in both trimesters (See Methods). As shown in Figure 1G, the

168 motif ratios significantly increased from PT2 (median: 1.45) to PT3 (median: 2.1)

(*P*-value<0.0001, Mann-Whitney U test). Both PT3 and PT2 samples exhibited
significantly increased motif ratios relative to the healthy pregnancies in the same
trimester (median motif ratio of NT3: 1.31, *P*-value<0.0001; median motif ratio of
NT2: 1.34, *P*-value<0.0001, Mann-Whitney U test). These results indicated that the
PE-specific motifs were capable of reflecting the PE disease signals.

We further compared the consistency of differential motifs among different comparison sets. According to Fig 1H-J, 48 increased and 43 decreased motifs were co-present across Sets A, B and C, accounting for 71.65%, 84.26% and 72.8% of the

177	motifs in Sets A, B and C, respectively. In contrast, only 10 increased and 2 decreased
178	motifs co-existed in all sets, accounting for 9.45%, 11.11%, 9.6% and 11.88% of
179	motifs in Set A, B, C and D. This result suggests that the motifs related to
180	preeclampsia pathology were not shared in normal pregnancies. Moreover, 23
181	increased and 8 decreased motifs overlapped between Set C and Set D, which were
182	deemed motifs altered with gestational ages, accounting for 24.8% and 30.69% of
183	motifs in Set C, and D, respectively (Figure 1H-J). These shared motifs were mostly
184	gestational physiology-related signals that coexisted in both preeclampsia and healthy
185	samples.

186 Correlation between gestational age and PE-specific motif abundance

187 In the Discovery cohort, 3 pregnant women in the control group and 8 pregnant 188 women in the PE group contributed samples during both 2nd trimester and 3rd 189 trimesters. These samples allowed us to further investigate how the PE-specific motif 190 signals (i.e. frequencies of motifs in set A) changed as the pregnancy progressed. As 191 shown in Figure 2A, most of the PE samples displayed enhanced trends for increased 192 and decreased Set A PE-specific motifs in PT3 compared with PT2. While the 193 PE-specific motif frequencies remained consistent between NT3 and NT2 samples 194 (Figure 2B), indicating the absence of PE signals in healthy pregnancies. In order to 195 quantify the enhancement of motif patterns, we calculated the accumulated deviations between motif frequencies in samples collected from 2nd and 3rd trimesters for each 196

197	pregnant woman. We termed this value as "motif distance". According to Fig 2C, the
198	PE samples showed dramatically higher motif distances than the control samples. 75%
199	(6/8) of the PE pregnancies showed enhanced motif patterns (i.e. motif distance >0),
200	but none of the healthy pregnancies exhibited this enhancement.

201 Correlation between fetal DNA fraction and gestational physiology-related motif

abundance

203 To assess the gestation-physiology signals in PE and healthy pregnancies, we 204 analyzed the correlation between set D motif ratios and fetal DNA fraction in 205 maternal plasma in samples of the two groups. The motif ratios were observed to be 206 significantly correlated with the fetal DNA fractions in healthy samples (Pearson r= 207 0.49, *P*-value<0.0001), further consolidating that the motifs in set D were mostly 208 gestation related and carry strong physiology signals (Figure 2D). However, the 209 correlation between Set C motifs ratio and the fetal DNA fraction in PE samples was 210 not significant (Figure 2E). This weak correlation in PE samples might be due to the 211 confounder of abundant PE pathology signals (i.e. PE-specific motifs in set C) 212 carried.

213 Early identification of EO-PE patients by PE-specific motif ratio

As the cfDNA ends motifs of PE patients showed distinct PE signatures, we wondered whether these PE-specific motifs could be used as diagnostic biomarkers in the early detection of preeclampsia during pregnancy. Hence, we further recruited an

217	independent pregnancy cohort containing early-onset severe PE (N=26, gestational
218	age: 17.5±2.9 weeks) and gestation-age-matched healthy (N=48, gestational age:
219	17.8 \pm 2.8 weeks) pregnancies in the 2 nd trimester as a validation cohort (Supplemental
220	Table 2) in the same hospital (SZ-2 cohort). The plasma samples were processed with
221	the same protocol and platform as the discovery cohort, with mean sequencing depths
222	of 19.03 (range: 9.73 - 87.84) and 22.61 (range: 8.32 - 103.27) for control and EO-PE
223	subjects, respectively. Motif ratios based on PE-specific motifs of Sets A and B from
224	the discovery cohort were analyzed in this validation cohort (See Methods). As shown
225	in Figure 3A and B, the median of motif ratios based on set A and B in EO-PE
226	samples were both significantly higher than healthy samples (median set A motif ratio:
227	1.45 vs 1.30, <i>P</i> -value<0.0001; median set B motif ratio: 1.28 vs 1.16, <i>P</i> -value<0.0001,
228	Mann-Whitney U test), in line with the observations in the discovery cohort (Figure
229	1G), which validated the robustness the PE-specific motifs. ROC curve analysis was
230	further employed to assess the classification performance between PE and healthy
231	pregnancies in this validation cohort by motif ratios. The AUC was 0.78 [95%
232	CI:0.65-0.92] for the PE determination based on motifs of set A, which was
233	comparable to the use of motifs of set B (AUC:0.77 [95% CI: 0.63-0.90]) (Figure
234	3C).

235 Early identification of EO-PE patients based on machine learning model

236 Since a single PE-motif ratio demonstrated the potential for PE identification, we

237 aimed to develop a machine-learning model based on PE-specific motifs to maximize 238 the PE prediction performance. As shown in Figure 4A, first, we extracted 91 239 PE-specific motifs shared among Sets A, B and C of the discovery cohort as the 240 model features. As the motifs were mined and validated in the pair-end sequencing 241 data with high sequencing depth, to assess the applicability and robustness of these 242 motif biomarkers in samples with different sequencing platforms, protocols, and 243 ultra-low sequencing depth, we further collected 2,481 sequencing samples from 244 pregnancies (Healthy pregnancy (HP): n=2445, EO-PE pregnancy: n=36) receiving 245 non-invasive pregnant testing (NIPT). From this dataset, we randomly selected 1,222 246 healthy samples and 18 EO-PE samples (NIPT-1 dataset) and combined them with the 247 discovery cohort as training samples. The remaining NIPT samples (NIPT-2 dataset) 248 were used as testing samples. A support vector machine (SVM) model for PE 249 detection was trained and determined through the 10-fold cross-validation (See 250 Methods). The prediction model was applied to the SZ-2 cohort and NIPT-2 dataset 251 for the EO-PE detection.

As a result, we obtained AUC values of 0.90 ± 0.06 for determining EO-PE patients in the training sample set (Figure 4B). Moreover, we achieved a high AUC of 0.83 [95% CI: 0.72-0.93] for EO-PE detection in the SZ-2 validation cohort (Figure 4C). Notably, even with ultra-low sequencing depth (0.05X) and single-end sequencing mode, we obtained a high AUC of 0.84 [95% CI: 0.74-0.92] for the NIPT-2 sample set (Figure 4D).

258

259 Tissue-of-origin of cfDNA carrying PE-specific motifs in preeclampsia pregnant

260 woman

261	The cell-free DNA in maternal plasma could be released by the fetus and the
262	mother. To explore whether the PE motif signals were specifically origin from the
263	fetus (i.e. placenta) or the mother (i.e. predominantly the hematopoietic cells), we
264	reanalyzed the plasma DNA of one healthy and one PE pregnant woman with
265	matched sequencing data of maternal and paternal buffy coat from our previously
266	published paper(31) (Figure 5A). Fetal- and maternal-derived cfDNA were
267	determined by the parental specific alleles (See Methods). We categorized the plasma
268	DNA into four origin groups: (1) PE-mother and (2) PE-fetus that differentiated from
269	the PE individual, (3) Control-mother and (4) Control-fetus that differentiated from
270	the healthy individual (Figure 5A).

As shown in Figure 5B, the plasma DNA originating from the fetuses was significantly shorter than mother-originated ones. Besides, the PE-mother derived cfDNA was observed to be longer than the cfDNA from the control-mother. To investigate whether the identified PE motif pattern is specific to either the mother or the fetus, we conducted a comparative analysis of motif frequencies between different sources of cfDNA, including (1) fetus-derived cfDNA from PE and control pregnancies, (2) maternal-derived cfDNA from PE and control pregnancies, as well as

278	mother-derived and fetus-derived cfDNA within the (3) PE patient and (4) healthy
279	pregnancy (Figure 5A and C). We calculated the log_{10} (Fold change) of 256 motifs in
280	terms of frequency within each of the four group comparisons and ranked the motifs
281	based on the $ \log_{10}$ (Fold change) . We took the top and bottom 25% of motifs with
282	positive log_{10} (Fold change) and top 25% of motifs with negative log_{10} (Fold change)
283	values as the differentially increased and decreased motifs in the latter pregnant
284	woman of the comparison (e.g. PE in the comparison of Control VS PE) (Figure 5C).
285	The motif pattern specific to preeclampsia, characterized by an enrichment of A- and
286	C-started motifs and a reduction of G and T motifs, was consistently observed in both
287	fetal-derived and maternal-derived cfDNA of PE pregnancy compared to those of the
288	healthy pregnant woman (Supplemental Figure 2 and Figure 5D). Notably, the A- and
289	C-started motifs accounted for 78.13% and 70.31% of the differentially increased
290	motifs, while the T- and G-started motifs accounted for 73.44% and 70.31% of the
291	differentially decreased motifs in PE-mother and PE-fetus derived cfDNA,
292	respectively, when compared with those in healthy pregnancy. However, this motif
293	pattern was absent in the comparison between fetus-derived cfDNA and
294	mother-derived cfDNA in either PE or control subjects. Among the increased motifs,
295	the A and C-started motifs only account for 42.19% and 42.19% in the fetus-derived
296	cfDNA compared to the mother derived in PE and control subjects, respectively.
297	Among the decreased motifs, the G and T-started motifs only account for 42.19% and
298	37.50% in the fetus-derived cfDNA compared to the mother derived in PE and control

299 subjects, respectively (Figure 5D).

300	Moreover, we compared the motif ratio of the top 10 increased and top 10
301	decreased motifs of set A between fetal cfDNA from both PE and healthy pregnancies,
302	and maternal cfDNA from both PE and healthy pregnancies. As shown in Figure 5E,
303	for PE-decreased motifs, 7 out of 10 in PE-fetus derived cfDNA and all of them in
304	PE-mother derived cfDNA showed consistently decreased patterns compared with
305	that origin in the healthy individual. Meanwhile, for PE-increased motifs, 9 out of 10
306	in PE-fetus derived cfDNA and all of them in PE-mother derived cfDNA showed
307	consistently increased patterns compared with that origin in healthy individuals
308	(Figure 5F). These results demonstrated that the PE-specific motif pattern co-existed
309	in both the fetal and maternal released DNA in plasma. Therefore, as the motif
310	differences observed in both the mother and fetus with preeclampsia exhibit
311	congruent patterns, we speculated that the fragmentation preference producing the
312	PE-specific motifs was non-tissue-specific and primarily attributable to extracellular
313	DNA molecule degradation, which might be influenced by nucleases in the plasma,
314	and shared the same pattern in both the mother and fetus.

315

316 Size and nucleosome footprint of cfDNA carrying different ending nucleotide

Ends motifs were generated from the fragmentation of cfDNA in plasma, whichwas influenced by both the nucleosome binding patterns(27) and the activity of

319	nuclease(32). Thus, to explore the potential fragmentation factors leading to the
320	preference of motifs in PE patients, we analyzed the size of DNA molecules and the
321	occurrence of cfDNA ending sites in relation to nucleosome centres. For each DNA
322	fragment, the upstream and downstream 5' ends were labelled as the U-end and D-end,
323	respectively (Figure 6A). We randomly selected 8 samples from each of the groups in
324	the discovery cohort and pooled them to represent that group.
325	First, we analyzed the content of cfDNA molecules carrying different nucleotides
326	(i.e. A, T, C and G) in the U-end (Figure 6B) and D-end (Supplemental Figure 3A)
327	within the size range of 50-250bp in all groups. As shown in Figure 6B, the PT2 and
328	PT3 groups showed consistently higher contents of cfDNA with A- and C-end and
329	consistently lower contents of cfDNA with G- and T-end compared with control
330	groups. Additionally, cfDNA with different ending nucleotides displayed dramatically
331	different proportion profiles. cfDNA with C-end showed the highest proportion
332	(i.e. >30%) among all groups across all sizes and displayed a predominant peak
333	around 166bp, which was reminiscent of the length of DNA wrapping the nucleosome
334	core, indicating that the nuclease cutting on C-end DNA may primarily occur on the
335	link DNA of nucleosome and contributed the majority of cfDNA. For short cfDNA
336	below 100bp, the proportions of cfDNA with A-end and C-end were initially higher
337	and decreased gradually. Conversely, for cfDNA ending with G and T, the proportions
338	of such cfDNA progressively increased below 150bp and exhibited a strong 10-bp
339	periodicity. These findings suggest that the components of cfDNA with different ends

340 at each size exhibit distinct preferences and fluctuate accordingly.

341	Figure 6C displays the size profiles of cfDNA with different U-end nucleotides
342	between 50bp and 120bp. The cfDNA with A-end exhibited a higher proportion of
343	short DNA (e.g. <120bp) among all groups. The cfDNA with C-end further showed a
344	slightly higher proportion in the PT2 group and a distinctly higher proportion in the
345	PT3 group. Similar patterns were also observed in cfDNA with different D-end
346	nucleotides (Supplemental Figure 3B). These results indicated that the PE-specific
347	cleavage signals existed in cfDNA across various sizes.
348	To explore whether the cfDNA with different ends would have different cutting
349	preferences in relation to nucleosome structure, we mapped the ending sites of cfDNA
350	with A, T, C, and G ends to the upstream and downstream regions of the nucleosome
351	core. Figure 6D illustrates the content of cfDNA with different U-ends in each
352	location relative to the nucleosome core. The cfDNA with different ends showed
353	distinct proportions across nucleosome structures. For example, the cfDNA with A
354	and G ends showed troughs around 75bp upstream to the nucleosome core, while the
355	cfDNA with C and T ends showed peaks at this location. The PE and control groups
356	showed consistent waveforms in the distributions of the cfDNA with the same ending
357	nucleotide. However, compared with control groups, the component of A-end and
358	C-end cfDNA were elevated in PT3 and PT2 groups, the component of G-end and
359	T-end cfDNA were reduced in PT3 and PT2 groups, across the 200bp regions around
360	the nucleosome core. The cfDNA distribution patterns in D-end are shown in

361 Supplemental Figure 3C. These results show that cfDNA with different ending
362 nucleotides undergoes distinct cutting patterns across nucleosome structures, whereas
363 PE cleavage patterns can occur throughout the entire nucleosome structure rather than
364 being limited to specific regions.

365

366 Nuclease levels in plasma DNA of healthy and PE pregnancies

367 The above findings revealed that the PE cleavage signals were present in all 368 cfDNA sizes and in regions surrounding the nucleosome core. We speculated that the 369 activity of nucleases in plasma might be altered and thus lead to systematically 370 different dynamics of fragmentation patterns. Figure 7A shows the cfDNA 371 concentrations in the plasma of different groups. The patients with preeclampsia were 372 observed to have significantly higher cfDNA levels than the healthy pregnancies at 373 both 2nd (median: 41.2 ng/µl vs 30 ng/µl, *P*-value<0.0001, Mann-Whitney U test) and 374 3^{rd} (median: 52.4 ng/µl vs 41.8 ng/µl, *P*-value=0.0001, Mann-Whitney U test) 375 trimesters, indicating the nuclease activity and cfDNA generation might be more 376 pronounced in PE patients in comparison to healthy pregnant women.

Previous studies(*32*) have implicated the involvement of nuclease DFFB and
Deoxyribonuclease I (DNASE1) in cfDNA fragmentation in plasma. Specifically,
DFFB has been shown to preferentially generate cfDNA with A ends, while DNASE1
is associated with the production of cfDNA with T-ends. Thus, we further quantified

381	the concentration of nuclease DFFB and DNASE1 in the plasma of 21 healthy and 15
382	EO-PE pregnancies during the 3 rd trimester. The median levels of DFFB were
383	approximately two-fold higher in PE subjects (median: 0.73 ng/ml, range: 0.25 ng/ml
384	-1.15 ng/ml) compared to healthy subjects (median: 0.36 ng/ml, range: 0.20 ng/ml
385	-1.66 ng/ml) (P-value=0.011, Mann-Whitney U test) (Figure 6F). This increase in
386	DFFB levels might contribute to the higher proportion of cfDNA with A ends
387	observed in PE pregnancies. Besides, we also observed significantly increased levels
388	of DNASE1 in PE patients (median: 4.00 ng/ml, range: 1.71 ng/ml -8.45 ng/ml)
389	compared with healthy individuals (median: 1.98 ng/ml, range: 0.86 ng/ml -9.22
390	ng/ml) (P-value=0.0110, Mann-Whitney U test) (Supplemental Figure 4).

391 Discussion

In this study, we investigated the end motif patterns in the plasma DNA of pregnancies with and without early-onset severe preeclampsia in different trimesters. Our findings revealed that these end motifs exhibit distinct pathological signatures in preeclampsia patients, while displaying physiological signatures in healthy pregnant women.

By leveraging the PE-specific motifs identified in the discovery cohort, we
successfully validated their utility as a highly effective biomarker for the early
detection of EO-PE in another independent cohort processed with a similar protocol.
Remarkably, incorporating the PE-specific motifs into a predictive model enabled us

401 to accurately identify PE patients even in samples from the NTPT group, which 402 underwent disparate protocols, including variations in library preparation, sequencing 403 platforms, ultra-low sequencing depth (~0.05X), and sequencing mode (35bp 404 single-end read). These findings reinforce the robustness and versatility of the 405 PE-specific motifs in early PE detection and highlight their potential for integration 406 into the current non-invasive prenatal testing protocol.

407 By deciphering the motifs in maternal- and fetal-derived cfDNA in maternal 408 plasma, we revealed that the PE-specific motif preference was likely generated within 409 the plasma rather than in the somatic tissue (e.g. placental). Furthermore, through 410 dissecting the component of cfDNA with different ending nucleotides at varying 411 lengths and nucleosome structures, we uncovered that the fragmentation process 412 leading to the formation of PE-specific motifs was enhanced across various sizes and 413 of the entirety nucleosome-wrapped cfDNA. Specifically, the 414 fragmentation-generating ends with nucleotides A and C showed systematic 415 enhancement. This led us to hypothesize that the DFFB nuclease(32), known for its 416 preference in generating cfDNA with A ends, might be involved in generating the 417 specific motif pattern associated with PE. Supporting this hypothesis, we have 418 observed a significant elevation in the concentration of DFFB in PE patients, 419 implying the potential role of DFFB nuclease in the etiopathology of preeclampsia. 420 Additionally, we observed a significant increase of DNASE1 in the plasma of PE 421 patients compared to healthy pregnancies. Previous studies (32) have suggested that

422	DNASE1 is prone to generating cfDNA molecules ending with T. However, in our
423	study, we observed a reduced frequency of cfDNA ending with T in the plasma of PE
424	patients, leading to a contradiction. One possible explanation for this discrepancy is
425	that a published research by Cheng et $al(33)$ has indicated that DNASE1 may not be a
426	major nuclease responsible for DNA digestion in plasma. Therefore, while the
427	concentration of DNASE1 increases in plasma, its impact on DNA fragmentation may
428	be negligible or counterbalanced by the activity of DFFB. Instead, DNASE1 has been
429	shown to play a major role in cfDNA fragmentation in $urine(34)$. Exploring the motifs
430	present at cfDNA ends and DNASE1 activity in urine, along with its relationship with
431	the onset of preeclampsia, would be a worthwhile avenue for further research.
432	Recently, using single-molecule sequencing, Yu et al(35). also reported a
433	preference of end motifs in the plasma DNA (a significant amount of long cfDNA,
434	e.g., >500bp) of PE patients in the third trimester. Their findings, however, differ from
435	our study in terms of the specific motif preferences observed. In our study, we
436	observed that the majority of increased motifs in PE patients were characterized by
437	ends with A and C (e.g., >95%), while the majority of decreased motifs in PE patients
438	were characterized by ends with T and G (e.g., >91%). In contrast, Yu et al. found that
439	motifs with reduced frequencies in preeclampsia predominantly ended with G or A,
440	while those with increased frequencies all ended with T or C. This inconsistency
441	suggests that the long DNA fragments captured by single-molecule sequencing may
442	originate from different fragmentation patterns compared to the short cfDNA

443 fragments sequenced by second-generation sequencing. These variations in 444 fragmentation patterns could potentially contribute to the observed differences in 445 motif preferences.

446 Despite the valuable insights gained from our study, there are certain limitations 447 that need to be addressed in future research. Firstly, our discovery cohort consisted 448 only of early-onset preeclampsia patients. Thus, a larger cohort containing multiple 449 types of preeclampsia collected from multiple centers is required to explore the 450 applicability of our findings to other types of preeclampsia. Another limitation of our 451 study is the lack of multiple sampling for the majority of pregnancies. Only 24 452 pregnant women were sampled twice in our study, which limits the exploration of the 453 earliest time for preeclampsia detection based on motif biomarkers. Including 454 multi-point sampling in future studies would also be highly valuable in monitoring the 455 progression of PE by capturing dynamic changes in the abundance of PE-specific 456 motifs.

In summary, our study highlights the potential of cfDNA end motif as a promising non-invasive biomarker for early detection of early-onset severe preeclampsia in pregnancy. Additionally, we have provided significant insights into the mechanisms involved in the generation and release of cfDNA from preeclampsia patients. By extending the clinical applications of cfDNA fragmentomics, our findings offer a valuable approach for the fast and cost-effective detection of pregnancy complications.

464				
465				
466				
467				
468				
469				
470				
471				
472				
473				
474				
475				
476				
477				
478	Methods			
479	Statistics			

We utilized Mann-Whitney U-test (Wilcoxon Rank Sum Tests) and the Kruskal-Wallis test to evaluate differences in continuous variables among different groups. For the comparison of categorical variables, we employed the Chi-square test or Fisher's exact test. Pearson's test was used to assess correlation. P-values below

- 484 0.05 were considered statistically significant. P-values less than 0.05, 0.01, 0.001, and
- 485 0.0001 were denoted by *, **, ***, and ****, respectively. We conducted the
- 486 statistical analysis using R software (version 3.6.1).

487 Study approval

- 488 Our study was approved by the Institutional Review Board of BGI (BGI-IRB
- 489 20040-T1) and the Institutional Review Board of Suzhou Municipal Hospital
- 490 (K-2019-019-K01).

491 **Data availability**

All data needed to evaluate the conclusions in the paper are present in the paper
and/or the Supplementary Materials. The key raw data have been deposited onto the
China National GeneBank DataBase (CNGBdb) with accession number
CNP0003056.

496 **Patients and samples**

- 497 For the discovery cohort (SZ-1 cohort), we recruited 140 singleton pregnancies
- 498 including healthy pregnancies and those diagnosed with preeclampsia, during the 2nd
- 499 and 3rd trimesters at the Suzhou Municipal Hospital, Jiang Su, China.
- 500 For the validation cohort (SZ-2 cohort), 26 PE and 48 healthy pregnancies, all in
- 501 the 2nd trimester, were further recruited at the same hospital.
- 502 For the NIPT cohort, the sequencing data of NIPT from 36 pregnancies who

503	developed early-onset severe PE and 2,445 healthy pregnancies accepted NIPT
504	between January 2016 and March 2021 were obtained from the Suzhou Municipal
505	Hospital, Jiang Su, China. The plasma cfDNA was sequenced by Illumina Hiseq
506	sequencing platform in a 35bp single-end format, resulting in a median of 3,497,067
507	sequencing reads (range: 1,060,392-11,201,854). From these samples, we randomly
508	selected 1,222 healthy samples and 18 EO-PE samples to be included in the training
509	dataset for the PE prediction model. The remaining samples were allocated for testing
510	the EO-PE prediction.
511	To quantify nuclease concentration in maternal plasma, we collected plasma
512	samples from 21 healthy pregnancies (8 samples were sequenced in the discovery
513	cohort) and 15 EO-PE pregnancies (12 samples were sequenced in the discovery
514	cohort) at the same hospital.
515	All participants involved in the study provided written informed consent. This
516	study was approved by the Ethics Committee of Suzhou Municipal Hospital
517	(K20190019H01) and the Institute Review Board of BGI (BGI-IRB 20040).
518	Sample collection and processing
519	Peripheral blood samples were collected from each subject using EDTA tubes. The
520	blood samples were centrifuged within 4 hours of collection at 1,600 \times g for 10
521	minutes at 4°C. Subsequently, the supernatant was isolated and centrifuged again at

522 $16,000 \times g$ for 10 minutes at 4°C. This process yielded 5ml of plasma.

523 Sequencing Library Preparation

Mini KF Kit (Magen, MD5432-02). DNA libraries were prepared using MGIEasy
Cell free DNA library preparation reagent kit (MGI, 1000007037) according to the
manufacturer's instructions. cfDNA concentration was measured by Qubit dsDNA HS
Assay Kit (Q32854, Invitrogen).

529 Quantification of Nuclease levels in plasma

For the quantification of human DFFB and DNASE1 levels in plasma, we used commercial enzyme-linked immunosorbent assay (ELISA) kits purchased from Jianglai Industrial (catalog number JL10215) and CUSABIO (catalog number CSB-E09068h). The assay values ranged from 0.15 ng/mL to 10 g/mL and 1.56 ng/mL to 100 ng/mL, respectively. The principle of the kit is based on the indirect sandwich ELISA technique, which utilizes a capture antibody and a biotin-labelled detection antibody for capture and detection purposes, respectively.

537 Sequencing and Alignment

The DNA libraries were sequenced using the DNBSEQ platform (MGI) in a 100bp ×
2 paired-end format. Fastp (v0.20.1)(*36*) was employed to remove adaptor sequences
and eliminate low-quality reads (i.e., quality score < 20) from the raw sequencing data.
Subsequently, Minimap2 (v2.2.11) was used to align the clean reads to the human
reference genome (GRCh38/hg38). PCR duplicates were filtered out using

543 Biobambam2 (v2-2.0.87)(*37*). Reads with more than three mismatches or aligning to 544 multiple locations were filtered. only paired-end reads that aligned to the same 545 chromosome with the correct orientation and had an insert size of ≤ 600 bp were 546 retained for downstream analysis.

547 Motif analysis

548 The 4-nucleotide sequence located at the 5' end of plasma DNA fragments is 549 previously defined as the ends motif(18). Motif frequency was computed by 550 normalizing the count of this specific motif against the total count of all 256 types of 551 4mer motifs. The motif diversity score based on the entropy principle, as described 552 before (18), was employed to gauge the uniformity of motif distribution. A low MDS 553 value indicated a skewed distribution, while a high MDS value indicated a more 554 uniform distribution of ends motifs in terms of their frequencies. Additionally, the 555 motif ratio was determined as the ratio between the accumulated frequencies of 556 increased motifs and decreased motifs.

557 Ends analysis

cfDNA molecules possess an upstream (U) and a downstream (D) 5' endpoint, determined by their coordinates on the human reference genome. We refer to these endpoints as the U-end and D-end, respectively. The U-end nucleotide can be one of the A/T/C/G bases, leading to the classification of cfDNA into UA/UT/UC/UG fragments. Similarly, the D-end nucleotide categorizes cfDNA into DA/DT/DC/DG

fragments. To achieve a high sequencing depth of cfDNA for deep investigation, we
randomly selected 8 samples from each group in the discovery cohort and pooled
them to represent the group. We analyzed and compared the size profiles of cfDNA
belonging to different categories.
Meanwhile, the occurrence of the ending sites of cfDNA from different categories

was interrogated across the 200bp region surrounding each of the nucleosome cores determined in the plasma DNA from Synder et al's paper (Figure 6A)(*17*). By accumulating and normalizing the cfDNA ends relative to the nucleosome cores within this 200bp region, we determined the composition of cfDNA with different end types at each location of this region, as well as the relative frequencies of cfDNA with a specific end type across the region.

574 Analysis of fetal- and maternal-derived DNA

575 The sequencing data of plasma DNA and paired parental genomic DNA of a healthy 576 and a preeclampsia pregnancy were obtained from our previous study(31). The 577 parental informative single-nucleotide polymorphisms (SNPs) where the mother was 578 homozygous (AA) and the fetus was heterozygous (i.e. fetus: AB, deduced from 579 father: AB/BB) were used for the differentiation of fetal- and maternal-derived 580 cfDNA in maternal plasma. We determined fetal-derived cfDNA based on those 581 molecules carrying fetal-specific alleles (B). Meanwhile, as the majority of cfDNA in 582 maternal plasma is mother released, the molecules carrying shared alleles (A) were 583 deemed as predominately maternal-derived.

584 **Development of Machine-learning model for EO-PE detection**

585	We identified 91 differential motifs that were shared among Sets A, B, and C in the
586	discovery cohort and utilized them as model features. The training dataset consisted
587	of all samples from the discovery cohort, along with a random selection of 1,222
588	control samples and 18 EO-PE samples. To train our EO-PE prediction model, we
589	employed the Support Vector Machine (SVM) algorithm and performed 10-fold
590	cross-validation. The hyperparameters and model that yielded the highest AUC value
591	in PE classification within the training sample set were selected as the final EO-PE
592	prediction model. We then evaluated the performance of the developed EO-PE
593	prediction model by applying it to the validation sets of the SZ-2 cohort and the
594	NIPT-2 dataset.

595 Fundings:

This work was supported by the National Natural Science Foundation of China (Grant
No. 82001576), Primary Research & Development Plan of Jiangsu Province
(BE2022736), Jiangsu Maternal and Children health care key discipline
(FXK202142), National Natural Science Foundation of China (32171441, 32000398),
National Key R&D Program of China (2022YFC2502402).

601 Competing interests

602 The authors declare that there is no competing interest in this study.

603

604 Author contributions

605	(Conception and design, HQ.Z., X.J., T.W.; sample collection and processing,									
606	LW.(Q., CH.Z., XJ.W., XY.S., H.T., Y.X., RJ.O., XX.W., Y.Z.; analysis and									
607	inter	pretation of data, HQ.Z., LW.Q., XT.H., Y.L., JY.Z., Y.S., X.J., T.W.; writing -									
608	origi	nal draft, HQ.Z., LW.Q., XT.H., Y.L., JY.Z.; writing - review & editing: HQ.Z.,									
609	LW.Q., XT.H., X.J., T.W.; All authors reviewed the manuscript and approved the final										
610	revis	ion.									
611											
612											
613	Refe	rence									
614											
615	1.	N. J. Kassebaum, R. M. Barber, Z. A. Bhutta, L. Dandona, P. W. Gething, S. I.									
616		Hay, Y. Kinfu, H. J. Larson, X. Liang, S. S. Lim, Global, regional, and national									
617		levels of maternal mortality, 1990–2015: a systematic analysis for the Global									
618		Burden of Disease Study 2015. The lancet 388 , 1775–1812 (2016).									
619	2.	N. J. Kassebaum, A. Bertozzi-Villa, M. S. Coggeshall, K. A. Shackelford, C.									
620		Steiner, K. R. Heuton, D. Gonzalez-Medina, R. Barber, C. Huynh, D. Dicker,									
621		Global, regional, and national levels and causes of maternal mortality during									
622		1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.									
623		<i>The Lancet</i> 384 , 980–1004 (2014).									

624	3.	J. M. Roberts, P. A. August,	G. Bakris, J.	. R. Barton, I. M.	Bernstein, M. Druzin.
					, ,

- R. R. Gaiser, J. P. Granger, A. Jeyabalan, D. D. Johnson, Hypertension in
 pregnancy: executive summary. *Obstetrics and Gynecology* 122, 1122–1131
 (2013).
- 628 4. D. Raymond, E. Peterson, A critical review of early-onset and late-onset
 629 preeclampsia. *Obstet Gynecol Surv* 66, 497–506 (2011).
- 630 5. A. L. Tranquilli, M. A. Brown, G. G. Zeeman, G. Dekker, B. M. Sibai, The
- 631 definition of severe and early-onset preeclampsia. Statements from the
- 632 International Society for the Study of Hypertension in Pregnancy (ISSHP).
- 633 Pregnancy Hypertension: An International Journal of Women's Cardiovascular
- 634 *Health* **3**, 44–47 (2013).
- 6. E. A. Steegers, P. von Dadelszen, J. J. Duvekot, R. Pijnenborg, Pre-eclampsia. *The Lancet* 376, 631–644 (2010).
- 637 7. E. Jung, R. Romero, L. Yeo, N. Gomez-Lopez, P. Chaemsaithong, A. Jaovisidha,
- F. Gotsch, O. Erez, The etiology of preeclampsia. *Am J Obstet Gynecol* 226,
 S844–S866 (2022).
- 640 8. O. Erez, R. Romero, E. Jung, P. Chaemsaithong, M. Bosco, M. Suksai, D. M.
- 641 Gallo, F. Gotsch, Preeclampsia and eclampsia: the conceptual evolution of a
 642 syndrome. *Am J Obstet Gynecol* 226, S786–S803 (2022).
- 643 9. T. M. MacDonald, S. P. Walker, N. J. Hannan, S. Tong, T. J. Kaitu'u-Lino,
- 644 Clinical tools and biomarkers to predict preeclampsia. *EBioMedicine* **75**, 103780

- 645 (2022).
- 646 10. L. A. Magee, K. H. Nicolaides, P. von Dadelszen, Preeclampsia. *New England*647 *Journal of Medicine* 386, 1817–1832 (2022).
- 648 11. T. R. Kolarova, H. S. Gammill, J. L. Nelson, C. M. Lockwood, R. Shree, At
- 649 Preeclampsia Diagnosis, Total Cell Free DNA Concentration is Elevated and
- 650 Correlates With Disease Severity. *J Am Heart Assoc* **10** (2021).
- A. C. Palei, Cell-free DNA as a potential biomarker for preeclampsia. *Expert Rev Mol Diagn* 21, 1253–1256 (2021).
- 653 13. Z. Guo, F. Yang, J. Zhang, Z. Zhang, K. Li, Q. Tian, H. Hou, C. Xu, Q. Lu, Z.
- 654 Ren, X. Yang, Z. Lv, K. Wang, X. Yang, Y. Wu, X. Yang, Whole Genome
- Promoter Profiling of Plasma DNA Exhibits Diagnostic Value for
 Placenta Origin Pregnancy Complications. *Advanced Science* 7, 1901819
 (2020).
- 658 14. R. W. K. Chiu, E. Heitzer, Y. M. D. Lo, F. Mouliere, D. W. Y. Tsui, Cell-Free
- 659 DNA Fragmentomics: The New "Omics" on the Block. *Clin Chem* 66,
 660 1480–1484 (2020).
- 661 15. K. C. A. Chan, J. Zhang, A. B. Y. Hui, N. Wong, T. K. Lau, T. N. Leung, K.-W.
- Lo, D. W. S. Huang, Y. M. D. Lo, Size Distributions of Maternal and Fetal DNA
 in Maternal Plasma. *Clin Chem* 50, 88–92 (2004).
- 664 16. K. Sun, P. Jiang, S. H. Cheng, T. H. T. Cheng, J. Wong, V. W. S. Wong, S. S. M.
- 665 Ng, B. B. Y. Ma, T. Y. Leung, S. L. Chan, T. S. K. Mok, P. B. S. Lai, H. L. Y.

666	Chan,	H.	Sun,	K.	C.	A.	Chan,	R.	W.	К.	Chiu,	Y. N	I. D	. Lo,	Orientation-	aware
-----	-------	----	------	----	----	----	-------	----	----	----	-------	------	------	-------	--------------	-------

- plasma cell-free DNA fragmentation analysis in open chromatin regions informs
 tissue of origin. *Genome Res* 29, 418–427 (2019).
- 669 17. M. W. Snyder, M. Kircher, A. J. Hill, R. M. Daza, J. Shendure, Cell-free DNA
- 670 Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin.
- 671 *Cell* **164**, 57–68 (2016).
- 672 18. P. Jiang, K. Sun, W. Peng, S. H. Cheng, M. Ni, P. C. Yeung, M. M. S. Heung, T.
- Kie, H. Shang, Z. Zhou, R. W. Y. Chan, J. Wong, V. W. S. Wong, L. C. Poon, T. Y.
- 674 Leung, W. K. J. Lam, J. Y. K. Chan, H. L. Y. Chan, K. C. A. Chan, R. W. K. Chiu,
- 675 Y. M. D. Lo, Plasma DNA End-Motif Profiling as a Fragmentomic Marker in
- 676 Cancer, Pregnancy, and Transplantation. *Cancer Discov* **10**, 664–673 (2020).
- 19. L. Serpas, R. W. Y. Chan, P. Jiang, M. Ni, K. Sun, A. Rashidfarrokhi, C. Soni, V.
- 678 Sisirak, W.-S. Lee, S. H. Cheng, Dnase113 deletion causes aberrations in length
- and end-motif frequencies in plasma DNA. Proceedings of the National
- 680 *Academy of Sciences* **116**, 641–649 (2019).
- 681 20. P. Jiang, K. Sun, Y. K. Tong, S. H. Cheng, T. H. T. Cheng, M. M. S. Heung, J.
- 682 Wong, V. W. S. Wong, H. L. Y. Chan, K. C. A. Chan, Y. M. D. Lo, R. W. K. Chiu,
- 683 Preferred end coordinates and somatic variants as signatures of circulating tumor
- 684 DNA associated with hepatocellular carcinoma. Proceedings of the National
- 685 *Academy of Sciences* **115** (2018).
- 686 21. K. C. A. Chan, P. Jiang, K. Sun, Y. K. Y. Cheng, Y. K. Tong, S. H. Cheng, A. I. C.

687		Wong, I. Hudecova, T. Y. Leung, R. W. K. Chiu, Y. M. D. Lo, Second generation
688		noninvasive fetal genome analysis reveals de novo mutations, single-base
689		parental inheritance, and preferred DNA ends. Proceedings of the National
690		Academy of Sciences 113 (2016).
691	22.	P. Jiang, T. Xie, S. C. Ding, Z. Zhou, S. H. Cheng, R. W. Y. Chan, WS. Lee, W.
692		Peng, J. Wong, V. W. S. Wong, H. L. Y. Chan, S. L. Chan, L. C. Y. Poon, T. Y.
693		Leung, K. C. A. Chan, R. W. K. Chiu, Y. M. D. Lo, Detection and
694		characterization of jagged ends of double-stranded DNA in plasma. Genome Res
695		30 , 1144–1153 (2020).
696	23.	Q. Zhou, G. Kang, P. Jiang, R. Qiao, W. K. J. Lam, S. C. Y. Yu, MJ. L. Ma, L. Ji,
697		S. H. Cheng, W. Gai, W. Peng, H. Shang, R. W. Y. Chan, S. L. Chan, G. L. H.
698		Wong, L. T. Hiraki, S. Volpi, V. W. S. Wong, J. Wong, R. W. K. Chiu, K. C. A.
699		Chan, Y. M. D. Lo, Epigenetic analysis of cell-free DNA by fragmentomic
700		profiling. Proceedings of the National Academy of Sciences 119 (2022).
701	24.	P. Ulz, G. G. Thallinger, M. Auer, R. Graf, K. Kashofer, S. W. Jahn, L. Abete, G.
702		Pristauz, E. Petru, J. B. Geigl, E. Heitzer, M. R. Speicher, Inferring expressed
703		genes by whole-genome sequencing of plasma DNA. Nat Genet 48, 1273–1278
704		(2016).

- 705 25. M. S. Esfahani, E. G. Hamilton, M. Mehrmohamadi, B. Y. Nabet, S. K. Alig, D.
- 706 A. King, C. B. Steen, C. W. Macaulay, A. Schultz, M. C. Nesselbush, J. Soo, J. G.
- 707 Schroers-Martin, B. Chen, M. S. Binkley, H. Stehr, J. J. Chabon, B. J. Sworder,

708	A. BY. Hui, M. J.	Frank, E. J. Mod	ling, C. L. Liu, A	. M. Newman, J. M. Isbell
	,	,	0, , ,	/

- 709 C. M. Rudin, B. T. Li, D. M. Kurtz, M. Diehn, A. A. Alizadeh, Inferring gene
- 710 expression from cell-free DNA fragmentation profiles. Nat Biotechnol 40,
- 711 585–597 (2022).
- 712 26. Y. M. D. Lo, D. S. C. Han, P. Jiang, R. W. K. Chiu, Epigenetics, fragmentomics,
- and topology of cell-free DNA in liquid biopsies. *Science (1979)* **372** (2021).
- 714 27. K. Sun, P. Jiang, A. I. C. Wong, Y. K. Y. Cheng, S. H. Cheng, H. Zhang, K. C. A.
- 715 Chan, T. Y. Leung, R. W. K. Chiu, Y. M. D. Lo, Size-tagged preferred ends in
- 716 maternal plasma DNA shed light on the production mechanism and show utility
- in noninvasive prenatal testing. *Proceedings of the National Academy of Sciences* 115 (2018).
- 719 28. W. Guo, X. Chen, R. Liu, N. Liang, Q. Ma, H. Bao, X. Xu, X. Wu, S. Yang, Y.
- Shao, F. Tan, Q. Xue, S. Gao, J. He, Sensitive detection of stage I lung
 adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. *EBioMedicine* 81, 104131 (2022).
- 723 29. L. Chen, G. K. Abou-Alfa, B. Zheng, J.-F. Liu, J. Bai, L.-T. Du, Y.-S. Qian, R.
- Fan, X.-L. Liu, L. Wu, J.-L. Hou, H.-Y. Wang, Genome-scale profiling of
 circulating cell-free DNA signatures for early detection of hepatocellular
 carcinoma in cirrhotic patients. *Cell Res* 31, 589–592 (2021).
- 727 30. Y. Wang, X. Fan, H. Bao, F. Xia, J. Wan, L. Shen, Y. Wang, H. Zhang, Y. Wei, X.
- 728 Wu, Y. Shao, X. Li, Y. Xu, S. Cai, Z. Zhang, Utility of Circulating Free DNA

729	Fragmentomics in the Prediction of Pathological Response after Neoadjuvant
730	Chemoradiotherapy in Locally Advanced Rectal Cancer. Clin Chem 69, 88–99
731	(2023).

- J. Ju, J. Li, S. Liu, H. Zhang, J. Xu, Y. Lin, Y. Gao, Y. Zhou, X. Jin, Estimation of
 cell-free fetal DNA fraction from maternal plasma based on linkage
 disequilibrium information. *NPJ Genom Med* 6, 85 (2021).
- 735 32. D. S. C. Han, M. Ni, R. W. Y. Chan, V. W. H. Chan, K. O. Lui, R. W. K. Chiu, Y.
- M. D. Lo, The biology of cell-free DNA fragmentation and the roles of DNASE1,
- 737 DNASE1L3, and DFFB. *The American Journal of Human Genetics* 106,
 738 202–214 (2020).
- 739 33. T. H. T. Cheng, K. O. Lui, X. L. Peng, S. H. Cheng, P. Jiang, K. C. A. Chan, R. W.
- 740 K. Chiu, Y. M. D. Lo, DNase1 does not appear to play a major role in the
- fragmentation of plasma DNA in a knockout mouse model. *Clin Chem* 64,
 406–408 (2018).
- 743 34. M. Chen, R. W. Y. Chan, P. P. H. Cheung, M. Ni, D. K. L. Wong, Z. Zhou, M.-J.
- L. Ma, L. Huang, X. Xu, W.-S. Lee, Fragmentomics of urinary cell-free DNA in
 nuclease knockout mouse models. *PLoS Genet* 18, e1010262 (2022).
- 746 35. S. C. Y. Yu, P. Jiang, W. Peng, S. H. Cheng, Y. T. T. Cheung, O. Y. O. Tse, H.
- 747 Shang, L. C. Poon, T. Y. Leung, K. C. A. Chan, Single-molecule sequencing
- reveals a large population of long cell-free DNA molecules in maternal plasma.
- 749 *Proceedings of the National Academy of Sciences* **118**, e2114937118 (2021).

- 750 36. S. Chen, Y. Zhou, Y. Chen, J. Gu, fastp: an ultra-fast all-in-one FASTQ
- 751 preprocessor. *Bioinformatics* **34**, i884–i890 (2018).
- 752 37. G. Tischler, S. Leonard, biobambam: tools for read pair collation based
- algorithms on BAM files. *Source Code Biol Med* 9, 13 (2014).

754

755

756 Tables

- 757 Table 1. Demographic and clinical characteristics of pregnant women with and
- 758 without EO-PE of the discovery cohort.

	Second trimester]	Third trimester		
Variables	Controls n=56	PE n=71	P value	Controls n=8	PE n=16	P value	
Maternal age, years	34(25-43)	34(24-43)	0.779	34(26-38)	33.5(27-41)	0.916	
BMI, kg/m ²	23.6±3.1	23.9±3.5	0.596	26.0±2.6	28.4±4.7	0.230	
Times of pregnancies	2.8±1.6	2.8±1.5	0.997	2.4±1.8	3.1±1.7	0.267	
Times of delivery	0.3±0.4	0.3±0.5	0.843	0.4±0.5	0.9±0.6	0.086	
GA at sampling, weeks	19.0±4.9	17.6±1.9	0.861	39.7±1.1	29.9±3.4	< 0.0001	
GA at PE was diagnosed, weeks	-	30.0±3.0	-	-	29.7±3.3	-	
GA at delivery, weeks	-	-	-	39.7±1.2	31.0±3.35	< 0.0001	
Natural delivery, %(n)	-	-	-	62.5(5)	6.25(1)	0.003	
Stillbirth, %(n)	-	-	-	0	6.25(1)	0.470	
Male fetus, %(n)	-	-	-	50 (4)	28.6(4)	0.315	
Birthweight, g	-	-	-	3187.5±322.7	1342.7±435.0	< 0.0001	

759 PE, pre-eclampsia; BMI, body mass index; GA, gestational age.

760 Values were given as mean±SD and median(range).

761 P value: The Chi-square test was used to test variables with a 0-1 distribution, such as

762 Natural delivery, Stillbirth, and Male fetus. The remaining continuous or discrete

variables, such as Maternal age, Times of pregnancies, and Birthweight, were

reamined applying the Mann Whitney U test, with the exception of BMI, which was

revaluated with the Unpaired T test.

766	Table S1. List of differential motifs from different comparisons in the discovery
767	cohort.
768	
769	Table S2. Demographic and clinical characteristics of pregnant women with and
770	
771	
772	
773	
774	
775	
776	
777	
778	
779	
780	
781	
782	
783	
784	
785	
786	
787	
788	
/89	
790 701	
791	
792	
793	
794	
796	
797	
798	
799	
800	
801	
802	

803 Figure legends

804 Figure 1. Identification of PE-specific motif pattern.



805

806	(A) Sample collection in the discovery cohort. (B) Boxplot analysis of motif diversity
807	score in plasma DNA from NT2, PT2, NT3 and PT3 groups. (C) Heatmap analysis of
808	frequencies of 256 4mer motifs between NT3 and PT3 groups. (D) Volcano plot
809	analysis of motifs with differential frequencies between different comparisons. The
810	red and blue dots indicate the motifs with a P-value below 0.01 and ranked in the top
811	25% and bottom 25% of the fold change, respectively, which were deemed as
812	specifically increased and decreased motifs in the latter group of the comparisons (e.g.
813	PT3 in the comparison of "NT3 VS PT3"). Gray dots represent non-differential motifs
814	that did not reach the thresholds. (E) Frequency of the first nucleotide at the 5' start of
815	all differential motifs in each comparison set. (F) The total percentage of T- and
816	G-end motifs in the decreased motifs and the total percentage of A- and C-end motifs
817	in the increased motif group for each group comparison. (G) Comparison of
818	PT3-specific (identified from NT3 VS PT3, Set A) motif ratios between NT2 and PT2
819	groups, and between NT3 and PT3 groups. Venn diagram analysis of increased motifs
820	(H) and decreased motifs (I) among different group comparisons. (J) Number of
821	motifs that overlapped between different group comparisons.



827 Figure 2. Motif distributions in pregnant women with different gestational ages.

(A) The frequencies of PE-specific motifs in plasma DNA samples collected from the
same PE pregnant woman during her second and third trimesters. (B) The frequencies
of PE-specific motifs in plasma DNA samples collected from the same healthy
pregnant woman during her second and third trimesters. (C) Boxplot analysis of motif

833	distance between plasma DNA of second and third trimesters in control and PE
834	samples. (D) Correlation between NT3-specific (Set D) motif ratio and fetal DNA
835	fraction in maternal plasma of healthy pregnant women. (E) Correlation between
836	PT3-specific (Set C) motif ratio and fetal DNA fraction in maternal plasma of
837	pregnant women with PE.
838	

- 839
- 840

841 Figure 3. PE-specific motif analysis in plasma DNA of SZ-2 validation cohort.





843 Boxplot of the motifs ratio in PE and control samples based on the PE-specific motifs

844 of Set A (A) and Set B (B). (C) ROC curve analysis between PE and control groups



846

847

848

849

850

851 Figure 4. PE prediction in SZ-2 and NIPT cohort based on SVM model



852

853 (A) Illustration of PE prediction using PE-specific motifs by SVM model. (B) ROC

854	curve analysis between PE and control groups in pooled training samples based on the
855	prediction model using 91 PE-specific motifs and the 10-fold cross-validation ROC
856	curve of EO-PE detection in SZ-2 cohort (C) and NIPT-2 sample set (D) based on PE
857	prediction model.
858	
859	
860	
861	
862	
863	
864	
865	
866	
867	
868	
869	
870	
871	
872	
873	
874	

875

876 Figure 5. Ends motif of fetal- and maternal-derived cfDNA in a healthy and a PE



877 pregnant woman.



880 with and without PE. Four sets of motif comparisons were performed between fetal-

881	and maternal-derived cfDNA and between PE and healthy pregnant women. (B) Size
882	profiles of fetal- and maternal-derived cfDNA in healthy and PE pregnant women. (C)
883	Volcano plot analysis of motifs with differential frequencies between different
884	comparisons. Y-axis indicates the rank of the motifs according to their frequency in
885	descending order. Red and blue dots indicate the motifs ranked in the top 25% and
886	bottom 25% of the fold change, respectively, which were deemed as specifically
887	increased and decreased motifs in the latter group of the comparisons. Gray dots
888	indicate those motifs below the thresholds, which were deemed as non-differential
889	motifs. (D) The total percentage of T- and G-end motifs in the decreased motifs and
890	the total percentage of A- and C-end motifs in the increased motif group for each
891	group comparison. Logarithmic scale representation of the ratio between frequencies
892	of top 10 PE-decreased motifs (E) and top 10 PE-increased motifs (F) of set A (based
893	on the discovery cohort) in plasma fetal- and maternal-derived cfDNA of PE and
894	healthy pregnant women.
895	
896	
897	
898	
899	
900	

901

902

903 Figure 6. Size and nucleosome footprint analysis for cfDNA carrying different

904 U-ends.



906 (A) Illustration of ends occurrence and coverage of cfDNA with different ends across
907 the genome. (B) Composition of plasma cfDNA with different U-ends in NT2, PT2,
908 NT3 and PT3 groups at each of the cfDNA lengths between 50 and 250bp. The

909	frequency of cfDNA at each individual size was determined by calculating the
910	number of cfDNA molecules with a specific ending nucleotide and normalizing it to
911	the total number of cfDNA molecules with the same size. (i.e. in each size, the
912	summed frequency of cfDNA with A, T, C and G ends was 100%). (C) Size profiles
913	of cfDNA with different U-ending nucleotides across 50 and 120bp in different
914	groups (i.e the frequency of cfDNA with particular ending nucleotides at each
915	individual cfDNA length was normalized by the amount of cfDNA with the same
916	ending nucleotides between 50 and 120bp). (D) Composition of cfDNA with different
917	U-ending nucleotides at each genomic location relative to nucleosome structure in
918	NT2, PT2, NT3 and PT3 groups. The occurrence of each type of cfDNA ends in each
919	relative position of nucleosome was normalized by the total number of ends in this
920	location.

921







924 (A) cfDNA concentration in the plasma of NT2, PT2, NT3 and PT3 groups. (B) The

925 concentrations of DFFB in the plasma of NT2, PT2, NT3 and PT3 groups.

926

927 Figure S1.

928 Top 10 motifs with specific increased frequencies (red) and top 10 motifs with 929 specific decreased frequencies (blue) in different motif sets identified in the discovery 930 cohort.

931

932 Figure S2.

Frequencies of motifs with different starting nucleotides among the increased motifs (red) and decreased motifs (blue) of (A) maternal-derived cfDNA of the PE pregnancy compared to those of the healthy pregnancy, (B) fetal-derived cfDNA of the PE pregnancy compared to those of the healthy pregnancy, (C) fetal-derived cfDNA compared to maternal-derived cfDNA of the PE pregnancy, (D) fetal-derived cfDNA compared to maternal-derived cfDNA of the healthy pregnancy.

939

940 Figure S3. Size and nucleosome footprint analysis for cfDNA carrying different 941 D-ends.

942 (A)Composition of plasma cfDNA with different D-ends in NT2, PT2, NT3 and PT3
943 groups at each of the cfDNA lengths between 50 and 250bp. (B) Size profiles of
944 cfDNA with different D-ending nucleotides across 50 and 120bp in different groups.
945 (C) Composition of cfDNA with different D-ending nucleotides at each genomic

946 location relative to nucleosome structure in NT2, PT2, NT3 and PT3 groups.

947 **Figure S4**.

948 The concentrations of DNASE1 in the plasma of NT2, PT2, NT3 and PT3 groups.